Eiman Y Ibrahim (Eiman Ibrahim)

Publication Activity (10 Years)

Years Active: 2021-2022
Publications (10 Years): 3

Top Topics

Transforming Growth Factor

Top Venues

NPJ breast cancer

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Julia Foldi, Andrea Silber, Emily S Reisenbichler, Kamaljeet Singh, Neal Fischbach, Justin Persico, Kerin Adelson, Anamika Katoch, Nina Horowitz, Donald Lannin, Anees Chagpar, Tristen Park, Michał Marczyk, Courtney Frederick, Trisha Burrello, Eiman Y Ibrahim, Tao Qing, Yalai Bai, Kim Blenman, David L Rimm, Lajos Pusztai
Author Correction: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer. NPJ breast cancer 8 (1) (2022)
Kim R M Blenman, Michał Marczyk, Thomas Karn, Tao Qing, Xiaotong Li, Vignesh Gunasekharan, Vesal Yaghoobi, Yalai Bai, Eiman Y Ibrahim, Tristen Park, Andrea L M Silber, Denise M Wolf, Emily Reisenbichler, Carsten Denkert, Bruno Valentin Sinn, Mariya Rozenblit, Julia Foldi, David L Rimm, Sibylle Loibl, Lajos Pusztai
Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (12) (2022)
Julia Foldi, Andrea Silber, Emily S Reisenbichler, Kamaljeet Singh, Neal Fischbach, Justin Persico, Kerin Adelson, Anamika Katoch, Nina Horowitz, Donald Lannin, Anees Chagpar, Tristen Park, Michał Marczyk, Courtney Frederick, Trisha Burrello, Eiman Y Ibrahim, Tao Qing, Yalai Bai, Kim Blenman, David L Rimm, Lajos Pusztai
Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer. NPJ breast cancer 7 (1) (2021)